secwatch.observer — SEC 8-K summary
======================================

Issuer:     IRONWOOD PHARMACEUTICALS INC (IRWD)
CIK:        0001446847
Form:       8-K
Filed at:   2023-02-16T23:59:59+00:00
Accession:  0001104659-23-022597
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ironwood reports FY 2022 GAAP net income $175M; FDA grants priority review for LINZESS pediatric sNDA
--------------------------------------------------------------------------------

- FY 2022 total revenues $410.6M (down ~1% YoY); GAAP net income $175.1M vs $528.4M in FY 2021.
- Q4 2022 total revenues $107.2M; GAAP net income $48.9M ($0.27 diluted EPS).
- Adjusted EBITDA for FY 2022 was $252M, up from $234M in FY 2021; cash and equivalents $656M.
- FDA granted priority review for LINZESS sNDA for pediatric functional constipation (ages 6-17); PDUFA date Q2 2023.
- CEO cited robust prescription demand but lower LINZESS sales growth due to retail channel inventory fluctuations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1446847/000110465923022597/0001104659-23-022597-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1446847/000110465923022597/tm236845d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-022597

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer